Search Login Register
mofezolac
(N 22)
Summary
2955
relevant articles (41 outcomes,
278 trials/studies)
found for this Bio-Agent
Description:
cyclooxygenase-1 selective inhibitor; structure given in first source; RN from Toxlit
Also Known As:
N 22; (3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid; (3,4-di-(4-methoxyphenyl)-5-isoxazolyl)acetic acid; 3,4-DMPIAA; N-22
Key Diseases for which mofezolac is
Relevant
-
Infection
:
4 outcomes 15 studies in 92 results
-
Neoplasms (Cancer)
:
4 outcomes 13 studies in 224 results
-
Hypertension (High Blood Pressure)
:
3 outcomes 10 studies in 62 results
-
Breast Neoplasms (Breast Cancer)
:
3 outcomes 5 studies in 38 results
-
Carcinoma (Carcinomatosis)
:
2 outcomes 9 studies in 87 results
Show All >>
Drugs Related to mofezolac
-
tranilast (N 5')
-
N 30
-
Cyclophosphamide (Cytoxan)
-
quetiapine (Seroquel)
-
Interferons
-
Ethanol (Ethyl Alcohol)
-
Methotrexate (Mexate)
-
Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
-
HLA-DR Antigens (HLA-DR)
-
Steroids
Show All >>
Therapies Related to mofezolac
-
Drug Therapy (Chemotherapy)
-
Transplants (Transplant)
-
Percutaneous Coronary Transluminal Angioplasty (PTCA)
-
Stem Cell Transplantation
-
Combination Drug Therapy (Combination Chemotherapy)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2008 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.